Decoding Isocitrate Dehydrogenase Mutant Astrocytomas through Proteomics: Breakthrough in Immune Hot Subtypes and New Directions for Precision Medicine
Abstract：Isocitrate dehydrogenase (IDH)-mutant astrocytomas are the main subtypes of adult diffuse gliomas. The World Health Organization (WHO) classification of central nervous system tumors (2021) has clearly defined them, but they still face the clinical dilemma of 'same histological grade, different prognosis'. The 5-year survival rate varies by up to 40% among patients with the same grade [1]. Traditional genomic or transcriptomic subtyping cannot reflect protein functional status and cannot fully explain this heterogeneity [2-4]. Recent studies integrating multi-dimensional technologies centered on proteomics have revealed a new subtype system for this tumor, solving the paradox of 'immune hot microenvironment with poor prognosis', providing a breakthrough perspective for precise diagnosis and treatment [5].
Machine-generated Keywords：
Publication Date：2025-12-20
Online Publishing Date：2026-01-16(First online date of this platform, not the publication date of the document)
Pages：1( 755 )